

R E M A R K S


The specification has been amended to add priority information. The claims have been amended to more particularly point out and distinctly claim the subject matter applicants regard as the invention. Support for new claim 24 can be found throughout the application as filed. Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made".

No new matter has been introduced.

Applicants believe that no fee is required for this submission. However, should a fee be due, please charge such fee to Deposit Account No. 08-3425

Respectfully submitted

Date: July 2, 2001

  
Michele M. Wales (Reg. No. 43,975)  
Attorney for Applicants

Human Genome Sciences, Inc.  
9410 Key West Avenue  
Rockville, MD 20850  
(301) 610-5772 (telephone)

MMW/CAW/ur

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Ruben et al.

Application Number: to be assigned

Group Art Unit: to be assigned

Filed: herewith

Examiner: to be assigned

Title: 47 Human Secreted Proteins

Attny. Docket No. PZ035P1C1

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification

**Please replace the first paragraph on page 1 with the following paragraph:**

This application is a continuation application of U.S. Application No. 09/591,316, filed June 9, 2000, which is hereby incorporated by reference in its entirety, which [This application] is a continuation-in-part of, and claims benefit under 35 U.S.C. § 120 of copending PCT international patent application Serial No: PCT/US99/29950 filed December 16, 1999 (published in English), which is hereby incorporated by reference in its entirety, which claims benefit under 35 U.S.C. § 119(e) based on U.S. Provisional Applications Nos. 60/113,006 filed December 18, 1998, and 60/112,809 filed December 17, 1998, which are hereby incorporated by reference in their entireties.

In the Claims:

Claim 17 has been amended as follows:

17. (Amended) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 [or the polynucleotide of claim 1].

T0202040-9562660